DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
2.
DaviesS.J., PhillipsL., GriffithsA.M., RussellL.H., NaishP.F., RussellG.I.What really happens to people on long-term peritoneal dialysis?Kidney Int1998; 54: 2207–17.
3.
TopleyN.Biocompatibility of peritoneal dialysis solutions and host defense.Adv Ren Replace Ther1996; 3: 309–11.
4.
TopleyN., AlobaidiH.M., DaviesM., ColesG.A., WilliamsJ.D., LloydD.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
5.
LiberekT., TopleyN., JorresA., ColesG.A., GahlG.M., WilliamsJ.D.Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
6.
LiberekT., TopleyN., JorresA., PetersenM.M., ColesG.A., GahlG.M.Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH.Nephron1993; 65: 260–5.
7.
VeechR.L.Physiological approaches to increase biocompatibility of peritoneal dialysis.Perit Dial Int1996; 16: 332–3.
8.
van BronswijkH., VerbrughH.A., HeeziusE.C., VerkooyenR.P., van der MeulenJ., VerhoefJ.Host defence in CAPD treatment: the effect of the dialysate on cell function.Contrib Nephrol1990; 85: 67–72.
AufrichtC., EndemannM., BidmonB., ArbeiterK., MuellerT., RegeleH.Peritoneal dialysis fluids induce the stress response in human mesothelial cells.Perit Dial Int2001; 21: 85–8.
11.
ArbeiterK., BidmonB., EndemannM., RuffingshoferD., MuellerT., RegeleH.Induction of mesothelial HSP-72 upon in vivo exposure to peritoneal dialysis fluid.Perit Dial Int2003; 23: 499–501.
12.
ArbeiterK., BidmonB., EndemannM., BenderT.O., EickelbergO., RuffingshoferD.Peritoneal dialysate fluid composition determines heat shock protein expression patterns in human mesothelial cells.Kidney Int2001; 60: 1930–7.
13.
JorresA., BenderT.O., WitowskiJ.Glucose degradation products and the peritoneal mesothelium.Perit Dial Int2000; 20(Suppl 5): S19–22.
14.
JorresA., GahlG.M., FreiU.Peritoneal dialysis fluid biocompatibility: does it really matter?Kidney Int Suppl1994; 48: S79–86.
15.
JorresA., BenderT.O., FinnA., WitowskiJ., FrohlichS., GahlG.M.Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function.Kidney Int1998; 54: 2184–93.
16.
JorresA.Innovative approaches to the preservation of the peritoneal membrane: from bench to bedside.Adv Ren Replace Ther2001; 8: 164–72.
DuweA., VasS., WeatherheadJ.Effects of the composition of peritoneal dialysis fluids on chemiluminescence, phagocytosis, and bacteriocidal activity in vitro.Infect Immun1981; 33: 130–5.
19.
DouvdevaniA., RapoportJ., KonfortiA., ZlotnikM., ChaimovitzC.The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes.Perit Dial Int1993; 13: 112–17.
20.
DouvdevaniA., RapoportJ., KonfortyA., YulzariR., MoranA., ChaimovitzC.Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages.J Am Soc Nephrol1995; 6: 207–13.
21.
JorresA., LudatK., LangJ., SanderK., GahlG.M., FreiU.Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines.J Am Soc Nephrol1996; 7: 2192–201.
22.
BeavisM.J., WilliamsJ.D., HoppeJ., TopleyN.Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent.Kidney Int1997; 51: 205–15.
TopleyN., MackenzieR.K., WilliamsJ.D.Macrophages and mesothelial cells in bacterial peritonitis.Immunobiology1996; 195: 563–73.
25.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
26.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
27.
DaviesS.J., BrownE.A., FrandsenN.E., RodriguesA.S., Rodriguez-CarmonaA., VychytilA.Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription.Kidney Int2005; 67: 1609–15.
28.
LiberekT., Lichodziejewska-NiemierkoM., Knopinska-PoslusznyW., SchaubT.P., KirchgessnerJ., Passlick-DeetjenJ.Generation of TNFα and interleukin-6 by peritoneal macrophages after overnight dwells with bicarbonate- or lactate-buffered dialysis fluid.Perit Dial Int2002; 22: 663–9.
29.
de FijterC.W., VerbrughH.A., PetersE.D., OeP.L., van der MeulenJ., VerhoefJ.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
30.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
31.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
32.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
33.
FerianiM.Use of different buffers in peritoneal dialysis.Semin Dial2000; 13: 256–60.
34.
HeimburgerO., MujaisS.Buffer transport in peritoneal dialysis.Kidney Int Suppl2003; 88: S37–42.
35.
HausmannM.J., RogachevB., WeilerM., ChaimovitzC., DouvdevaniA.Accessory role of human peritoneal mesothelial cells in antigen presentation and T-cell growth.Kidney Int2000; 57: 476–86.
36.
TopleyN., KaurD., PetersenM.M., JorresA., WilliamsJ.D., FaictD.In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function.J Am Soc Nephrol1996; 7: 218–24.
37.
BajoM.A., del PesoG., CastroM.A., DiazC., CastroM.J., GilF.Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo.Adv Perit Dial2001; 17: 37–41.
38.
HoffC.M.In vitro biocompatibility performance of Physioneal.Kidney Int Suppl2003; 88: S57–74.
39.
FusshoellerA., PlailM., GrabenseeB., PlumJ.Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.Nephrol Dial Transplant2004; 19: 2101–6.
WitowskiJ., KorybalskaK., KsiazekK., Wisniewska-ElnurJ., JorresA., LageC.Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.Nephrol Dial Transplant2004; 19: 917–24.
42.
MontenegroJ., SarachoR.M., MartinezI.M., MunozR.I., OcharanJ.J., ValladaresE.Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions.Perit Dial Int2006; 26: 89–94.
43.
LeeH.Y., ParkH.C., SeoB.J., DoJ.Y., YunS.R., SongH.Y.Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).Perit Dial Int2005; 25: 248–55.
44.
WongT Y., PhillipsA.O., WitowskiJ., TopleyN.Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent.Kidney Int2003; 63: 1404–16.
45.
MacKenzieR.K., HolmesC.J., MoseleyA., JenkinsJ.P., WilliamsJ.D., ColesG.A.Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion.J Am Soc Nephrol1998; 9: 1499–506.
46.
MackenzieR.K., JonesS., MoseleyA., HolmesC.J., ArgyleR., WilliamsJ.D.In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function.Am J Kidney Dis2000; 35: 112–21.
47.
NauB., SchmittC.P., AlmeidaM., ArbeiterK., ArdissinoG., BonzelK.E.BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in bio-compatible peritoneal dialysis solutions in children [ISRCTN81137991].BMC Nephrol2004; 5: 14.
48.
GrossinN., WautierM-P, WautierJ-L, GaneP., TaammaR., BoulangerE.Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid.Perit Dial Int2006; 26: 664–70.
49.
BeelenR.H., HekkingL.H., ZareieM., van den BornJ.Rat models in peritoneal dialysis.Nephrol Dial Transplant2001; 16: 672–4.
50.
FerianiM., KirchgessnerJ., La GrecaG., Passlick-DeetjenJ.Randomized long-term evaluation of bicarbonate-buffered CAPD solution.Kidney Int1998; 54: 1731–8.
51.
FerianiM., Passlick-DeetjenJ., Jaeckle-MeyerI., La GrecaG.Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients.Nephrol Dial Transplant2004; 19: 195–202.
